BioFocus DPI, a leading provider of gene-to-candidate discovery services, and TET Systems Holding, a privately-held, German-based biotech company, have entered into an agreement to apply TET System's inducible gene technology in high-throughput screening campaigns performed for BioFocus DPI customers.

BioFocus DPI will offer TET Technology as part of its drug discovery screening service. Through this technology, the activity of individual genes can be controlled quantitatively and reversibly in cellular assays. This approach is particularly powerful in cases where the target is not well tolerated in the cells, since the protein will not be expressed until required for screening.

"The TET Technology allows us to build on the proven compound screening service that we offer clients. This powerful approach will benefit discovery programmes that are hindered by difficult to express targets. Using this technology, we will be able to perform more efficient, extensive compound screening on these problematic targets," commented Dr. Kate Hilyard, VP Biological Sciences, BioFocus DPI.

"We are very pleased to sign this agreement with BioFocus DPI, one of the leading drug discovery service providers worldwide. TET Technology has been used successfully for many years by most of the major pharmaceutical companies. Through this new partnership with BioFocus DPI, a broader range of pharmaceutical and biotechnology companies will gain access to TET System's gene expression technology," stated Dr. Ernst Boehnlein, CEO of TET Systems Holding and IP Merchandisers.